摘要
目的评估阿立哌唑+碳酸锂应用在双相情感障碍(BD)伴睡眠障碍(SD)患者中的效果。方法纳入宁德市福鼎精神病人疗养院2022年1月至2023年12月的100例BD伴SD患者,在随机数表法指导下分组,对照组50例(口服碳酸锂),观察组50例(口服阿立哌唑+碳酸锂),评价组间倍克-拉范森躁狂量表(BRMS)、汉密尔顿抑郁量表(HAMD)、SDRS、健康调查量表36(SF-36)、阳性与阴性症状量表(PANSS)及药物风险事件发生情况。结果治疗3个月后,观察组BRMS、HAMD、SDRS、PANSS均较对照组更低,SF-36评分较对照组更高,药物风险事件更少(P<0.05)。结论对BD伴SD患者采用阿立哌唑+碳酸锂治疗可减轻躁狂、抑郁症状,改善睡眠、生活质量、精神症状,减少药物风险事件。
Objective To evaluate the efficacy of aripiprazole+lithium carbonate in patients with bipolar disorder(BD)accompanied by sleep disorders(SD).Methods A total of 100 BD patients with SD from January 2022 to December 2023 were enrolled in the Fuding Psychiatric Sanatorium in Ningde City.Under the guidance of a random number table method,they were divided into two groups:a control group of 50 cases(lithium carbonate)and an observation group of 50 cases(aripiprazole+lithium carbonate).The intergroup evaluation included the Beck Raphanson Mania Scale(BRMS),Hamilton Depression Scale(HAMD),SDRS,Health Survey Scale 36(SF-36),Positive and Negative Symptom Scale(PANSS),and drug risk events.Results After 3 months of treatment,the observation group had lower levels of BRMS,HAMD,SDRS,and PANSS compared to the control group,higher SF-36 scores,and fewer drug risk events(P<0.05).Conclusions Treatment with aripiprazole and lithium carbonate in patients with BD and SD can reduce symptoms of mania and depression,improve sleep,quality of life,and psychiatric symptoms,and reduce drug risk events.
作者
上官修齐
林植辉
李园园
SHANGGUAN Xiuqi;LIN Zhihui;LI Yuanyuan(Department of Psychiatric WardⅡ,Ningde Fuding Mental Health Sanatorium,Ningde,Fujian 355200,China)
出处
《中国医药指南》
2025年第20期84-86,共3页
Guide of China Medicine
